Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Brennan, Ixchel M ^a   Feltrin, Kate L ^a   Horowitz, Michael ^a   Smout, Andre J P M ^b   Meyer, James H ^a   Wishart, Judith ^a   Feinle Bisset, Christine ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cholecystokinin; Glucagon like peptide 1

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; GLUCAGON LIKE PEPTIDE 1; SODIUM CHLORIDE;

ADULT; APPETITE; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DUODENUM MOTILITY; FEEDING BEHAVIOR; FOOD INTAKE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; MALE; MEAL; MOLECULAR WEIGHT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ANTRUM; STOMACH PRESSURE;

ADOLESCENT; ADULT; APPETITE; CHOLECYSTOKININ; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DUODENUM; ENERGY INTAKE; GASTROINTESTINAL MOTILITY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NAUSEA; PEPTIDE FRAGMENTS; PRESSURE; PROTEIN PRECURSORS; PYLORIC ANTRUM; REFERENCE VALUES; SATIETY RESPONSE;

EID: 19344374606     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00732.2004     Document Type: Article

References (45)

1. Anvari M, Paterson CA, Daniel EE, and McDonald TJ. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci 43: 1133-1140, 1998.
2. Beglinger C, Degen L, Matzinger D, D'Amato M, and Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 280: R1149-R1154, 2001.
3. Boyd KA, O'Donovan DG, Doran S, Wishart J, Chapman IM, Horowitz M, and Feinle C. High-fat diet effects on gut motility, hormone, and appetite responses to duodenal lipid in healthy men. Am J Physiol Gastrointest Liver Physiol 285: G188-G196, 2003.
4. Cook CG, Andrews JM, Jones KL, Wittert GA, Chapman IM, Morley JE, and Horowitz M. Effects of small intestinal nutrient infusion on appetite and pyloric motility are modified by age. Am J Physiol Regul Integr Comp Physiol 273: R755-R761, 1997.
5. Feinle C, Chapman IM, Wishart J, and Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in healthy and obese men. Peptides 23: 1491-1495, 2002.
6. Feinle C, Grundy D, and Read NW. Effects of duodenal nutrients on sensory and motor responses of the human stomach to distension. Am J Physiol Gastrointest Liver Physiol 273: G721-G726, 1997.
7. Feinle C, O'Donovan DG, Doran S, Andrews JM, Wishart J, Chapman I, and Horowitz M. Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol Gastrointest Liver Physiol 284: G798-G807, 2003.
8. Feltrin KL, Little TJ, Meyer JH, Horowitz M, Smout AJ, Wishart J, Pilichiewicz AN, Rades T, Chapman IM, and Feinle-Bisset C. Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 287: R524-R533, 2004.
9. Flint A, Raben A, Astrup A, and Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
10. Fraser R, Fone D, Horowitz M, and Dent J. Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans. Gut 34: 33-37, 1993.
11. Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, and Rovati L. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101: 503-511, 1991.
12. Geary N, Kissileff HR, Pi-Sunyer FX, and Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol Regul Integr Comp Physiol 262: R975-R980, 1992.
13. Gomez Cerezo J, Codoceo R, Fernandez Calle P, Molina F, Tenias JM, and Vazquez JJ. Basal and postprandial cholecystokinin values in chronic pancreatitis with and without abdominal pain. Digestion 48: 134-140, 1991.
14. Gutzwiller JP, Degen L, Matzinger D, Prestin S, and Beglinger C. Interaction between GLP-1 and CCK33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 287: R562-R567, 2004.
15. Gutzwiller JP, Drewe J, Ketterer S, Hildebrand P, Krautheim A, and Beglinger C. Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans. Am J Physiol Regul Integr Comp Physiol 279: R189-R195, 2000.
16. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, and Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44: 81-86, 1999.
17. Heddle R, Collins PJ, Dent J, Horowitz M, Read NW, Chatterton B, and Houghton LA. Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. J Gastroenterol Hepatol 4: 437-447, 1989.
18. Heddle R, Dent J, Toouli J, and Read NW. Topography and measurement of pyloric pressure waves and tone in humans. Am J Physiol Gastrointest Liver Physiol 255: G490-G497, 1988.
19. Hellstrom PM and Naslund E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol Behav 74: 735-741, 2001.
20. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, and Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126, 1995.
21. Kissileff HR, Carretta JC, Geliebter A, and Pi-Sunyer FX. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 285: R992-R998, 2003.
22. Kissileff HR, Pi-Sunyer FX, Thornton J, and Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34: 154-160, 1981.
23. Lilja P, Wiener I, Inoue K, Fried GM, Greeley GHJ, and Thompson JC. Release of cholecystokinin in response to food and intraduodenal fat in pigs, dogs, and man. Surg Gynecol Obstet 159: 557-561, 1984.
24. Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, and Morgan LM. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 81: 273-279, 1999.
25. MacIntosh CG, Andrews JM, Jones KL, Wishart JM, Morris HA, Jansen JB, Morley JE, Horowitz M, and Chapman IM. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide-YY and their relation to appetite and pyloric motility. Am J Clin Nutr 69: 999-1006, 1999.
26. MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JB, Horowitz M, and Chapman IM. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 86: 5830-5837, 2001.
27. Näslund E, Gutniak M, Skogar S, Rossner S, and Hellström PM. Glucagon-like peptide-1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68: 525-530, 1998.
28. Näslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, and Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91: 439-446, 2004.
29. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, and Schmiegel WH. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
30. Parker B, Sturm K, MacIntosh CG, Feinle C, Horowitz M, and Chapman IM. Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr 58: 212-218, 2004.
31. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, and Jones KL. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 3829-3834, 2003.
32. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, and Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38: 916-919, 1996.
33. Raybould HE and Tache Y. Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats. Am J Physiol Gastrointest Liver Physiol 255: G242-G246, 1988.
34. Rayner CK, Park HS, Doran SM, Chapman IM, and Horowitz M. Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia. Am J Physiol Gastrointest Liver Physiol 278: G98-G104, 2000.
35. Ritzel R, Orskov C, Holst JJ, and Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725, 1995.
36. Samsom M, Roelofs JM, Akkermans LM, van Berge Henegouwen GP, and Smout AJ. Proximal gastric motor activity in response to a liquid meal in type I diabetes mellitus with autonomie neuropathy. Dig Dis Sci 43: 491-496, 1998.
37. Santangelo A, Peracchi M, Conte D, Fraquelli M, and Porrini M. Physical state of meal affects gastric emptying, cholecystokinin release and satiety. Br J Nutr 80: 521-527, 1998.
38. Schirra J, Houck P, Wank U, Arnold R, Goke B, and Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46: 622-631, 2000.
39. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, and Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1 (7-36)amide in humans. J Clin Invest 101: 1421-1430, 1998.
40. Stunkard AJ and Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 29: 71-83, 1985.
41. Sturm K, MacIntosh CG, Parker BA, Wishart J, Horowitz M, and Chapman IM. Appetite, food intake and plasma concentrations of cholecystokinin, ghrelin and other gastrointestinal hormones in under-nourished older women and well-nourished young and older women. J Clin Endocrinol Metab 88: 3747-3755, 2003.
42. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389, 2001.
43. Wisen O, Bjorvell H, Cantor P, Johansson C, and Theodorsson E. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept 39: 43-54, 1992.
44. Wishart JM, Horowitz M, Morris HA, Jones KL, and Nauck MA. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 19: 1049-1053, 1998.
45. Xu X, Zhu H, and Chen JD. Pyloric electrical stimulation reduces food intake by inhibiting gastric motility in dogs. Gastroenterology 128: 43-50, 2005.